ethyl 2-chloro-2-(hydroxyamino)acetate | 753479-64-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: ethyl 2-chloro-2-(hydroxyamino)acetate
• CAS: 753479-64-0
• 化学式: C₄H₈ClNO₃
• 分子量: 153.565
• InChiKey: PLWDXYITTPOTKK-UHFFFAOYSA-N

物化性质

• 沸点：
  235.7±50.0 °C(Predicted)
• 密度：
  1.322±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  9
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  58.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  ethyl 2-chloro-2-(hydroxyamino)acetate 、 (2S)-3-(4-{[3-(2,3-dichlorophenyl)isoxazol-5-yl]methyl}piperazinyl)-1-(2-methylbenzothiazol-5-yloxy)propan-2-ol 、 对三氟甲基苯乙烯 在 三乙胺 作用下， 以 四氢呋喃 、 乙酸乙酯 为溶剂， 生成 ethyl 5-(4-(trifluoromethyl)phenyl)-4,5-dihydroisoxazole-3-carboxylate
  参考文献：
  名称：

  Substituted heterocyclic compounds

  摘要：

  本发明涉及新型杂环衍生物，可用于治疗各种疾病状态，特别是心血管疾病，如心房和心室心律失常，间歇性跛行，普林兹梅塔尔（变异）心绞痛，稳定和不稳定心绞痛，运动诱发性心绞痛，充血性心力衰竭和心肌梗死。这些化合物还可用于治疗糖尿病，并提高哺乳动物的高密度脂蛋白血浆水平。

  公开号：

  US20040176383A1

文献信息

• [EN] IMIDAZOPYRIMIDINES AS MODULATORS OF IL-17<br/>[FR] IMIDAZOPYRIMIDINES EN TANT QUE MODULATEURS DE L'IL-17
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2021220183A1

  公开（公告）日：2021-11-04

  The present application discloses compounds of Formula I or pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, and R5 are defined in the specification, as well as methods of making and using the compounds disclosed herein for treating or ameliorating an IL-17 mediated syndrome, disorder and/or disease.

  本申请公开了化合物I的化学式或其药用盐，其中R1、R2、R3、R4和R5在规范中有定义，以及制备和使用此处公开的化合物的方法，用于治疗或改善IL-17介导的综合症、紊乱和/或疾病。
• HETEROCYCLIC BENZIMIDAZOLES AS TRPM8 MODULATORS
  申请人：Player Mark R.

  公开号：US20100093788A1

  公开（公告）日：2010-04-15

  Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula I as follows: wherein W 1 , W 2 , W 3 , R 1 , R 1a , R 2 , R 2a , R 3 , V, Q, and X are defined herein.

  本发明涉及化合物、组合物和治疗各种疾病、综合征、病况和障碍的方法，包括疼痛。这些化合物由以下公式I表示：其中，W1、W2、W3、R1、R1a、R2、R2a、R3、V、Q和X的定义如下。
• Heterocyclic benzimidazoles as TRPM8 modulators
  申请人：Janssen Pharmaceutica N.V.

  公开号：US08232409B2

  公开（公告）日：2012-07-31

  Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula I as follows: wherein W1, W2, W3, R1, R1a, R2, R2a, R3, V, Q, and X are defined herein.

  本发明涉及化合物、组合物和方法，用于治疗各种疾病、综合症、状况和疾患，包括疼痛。这些化合物由以下式子I所表示：其中，W1、W2、W3、R1、R1a、R2、R2a、R3、V、Q和X在此定义。
• Design and Optimization of Benzimidazole-Containing Transient Receptor Potential Melastatin 8 (TRPM8) Antagonists
  作者：Daniel J. Parks、William H. Parsons、Raymond W. Colburn、Sanath K. Meegalla、Shelley K. Ballentine、Carl R. Illig、Ning Qin、Yi Liu、Tasha L. Hutchinson、Mary Lou Lubin、Dennis J. Stone、Judith F. Baker、Craig R. Schneider、Jianya Ma、Bruce P. Damiano、Christopher M. Flores、Mark R. Player

  DOI：10.1021/jm101075v

  日期：2011.1.13

  Transient receptor potential melastatin 8 (TRPM8) is a nonselective cation channel that is thermo-responsive to cool to cold temperatures (8-28 degrees C) and also may be activated by chemical agonists such as menthol and Antagonism of TRPM8 activation is currently under investigation for the treatment of painful conditions related to cold, such as cold allodynia and cold hyperalgesia The design, synthesis, and optimization of a class of selective TRPM8 antagonists based on a benzimidazole scaffold is described, leading to the identification of compounds that exhibited potent antagonism of TRPM8 in cell-based functional assays for human, rat, and canine TRPM8 channels Numerous compounds in the series demonstrated excellent in vivo activity in the TRPM8-selective "wet-dog shakes" (WDS) pharmacodynamic model and in the rat chronic constriction injury (CCI)-induced model of neuropathic pain Taken together the present results suggest that the in vivo antagonism of TRPM8 constitutes a viable new strategy for treating a variety of disorders associated with cold hypersensitivity, including certain types of neuropathic pain
• [EN] BENZIMIDAZOLES AS MODULATORS OF IL-17<br/>[FR] BENZIMIDAZOLES UTILISÉS EN TANT QUE MODULATEURS D'IL-17
  申请人：[en]JANSSEN PHARMACEUTICA NV

  公开号：WO2023049888A1

  公开（公告）日：2023-03-30

  The present application discloses compounds of Formula (I): (I), or pharmaceutically acceptable salt thereof, wherein R1, R2, R3, and R4are defined in the specification, as well as methods of making and using the compounds disclosed herein for treating or ameliorating an IL-17 mediated syndrome, disorder and/or disease.